Pila Pharma

Pila Pharma EBIT

The EBIT of Pila Pharma (PILA.ST) as of Nov 4, 2026 is -7.89 M SEK. In the previous year, EBIT was -8.11 M SEK — a change of -2.65% (higher).

EBIT

-7.89 MSEK

YoY

-2.65%

Last updated:

In 2025, Pila Pharma's EBIT was -7.89 M SEK, a -2.65% increase from the -8.11 M SEK EBIT recorded in the previous year.

The Pila Pharma EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2021
-9.26 M SEK
Jan 1, 2022
-8.89 M SEK
Jan 1, 2023
-6.39 M SEK
Jan 1, 2024
-8.11 M SEK
Jan 1, 2025
-7.89 M SEK
Jan 1, 2026 (e)
-1.34 M SEK
Jan 1, 2027 (e)
-1.60 M SEK
Jan 1, 2028 (e)
-1.90 M SEK
The Pila Pharma EBIT history
YEAREBITYoY
est-1.90 MSEK+19.05%
est-1.60 MSEK+19.05%
est-1.34 MSEK-83.00%
-7.89 MSEK-2.65%
-8.11 MSEK+26.84%
-6.39 MSEK-28.09%
-8.89 MSEK-4.00%
-9.26 MSEK+174.03%
-3.38 MSEK-61.01%
-8.67 MSEK+75.11%
-4.95 MSEK+3.28%
-4.79 MSEK+226.29%
-1.47 MSEK+63.23%
-899,850.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pila Pharma Revenue

Pila Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
719,230.00 SEK
-9.26 M SEK
-17.21 M SEK
Jan 1, 2022
1.88 M SEK
-8.89 M SEK
-26.78 M SEK
Jan 1, 2023
1.46 M SEK
-6.39 M SEK
-9.93 M SEK
Jan 1, 2024
775,000.00 SEK
-8.11 M SEK
-11.24 M SEK
Jan 1, 2025
1.13 M SEK
-7.89 M SEK
-16.86 M SEK
Jan 1, 2026 (e)
0.00 SEK
-1.34 M SEK
-5.47 M SEK
Jan 1, 2027 (e)
0.00 SEK
-1.60 M SEK
-9.68 M SEK
Jan 1, 2028 (e)
1.90 M SEK
-1.90 M SEK
-10.94 M SEK

Pila Pharma Margins

Pila Pharma stock margins

The Pila Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pila Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pila Pharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
94.68 %
-1,287.57 %
-2,392.46 %
Jan 1, 2022
100.00 %
-472.69 %
-1,423.74 %
Jan 1, 2023
100.00 %
-436.99 %
-678.73 %
Jan 1, 2024
-1,048.28 %
-1,046.32 %
-1,450.45 %
Jan 1, 2025
-509.32 %
-700.44 %
-1,496.27 %
Jan 1, 2026 (e)
-509.32 %
- %
- %
Jan 1, 2027 (e)
-509.32 %
- %
- %
Jan 1, 2028 (e)
-509.32 %
-100.00 %
-575.42 %

Pila Pharma Stock analysis

What does Pila Pharma do? Pila Pharma AB develops pharmaceutical products, focusing on XEN-D0501, a TRPV1 antagonist for type 2 diabetes treatment. The company conducts phase 2 clinical trials, including PP-CT01 and PP-CT02, which confirmed XEN-D0501's tolerability and potential for fewer side effects compared to existing treatments. Pila Pharma AB generates revenue through research and development of its patent-protected product candidate, targeting early-stage diabetes patients requiring oral medication to restore insulin production and lower blood sugar levels. The firm's primary product, XEN-D0501, is an orally administered tablet designed for early diabetes management. Clinical trials have shown positive results, supporting the product's safety profile and efficacy. Pila Pharma AB's business model centers on advancing its proprietary drug candidate through clinical development to secure regulatory approval and commercialization in the pharmaceutical market. Pila Pharma AB targets healthcare providers and patients with type 2 diabetes seeking innovative treatment options. The company's focus on phase 2 clinical trials positions it to address unmet medical needs in diabetes care, leveraging its patent-protected technology to differentiate XEN-D0501 from competitors. The firm's revenue stream depends on successful clinical outcomes leading to market entry of XEN-D0501. Pila Pharma is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Pila Pharma's EBIT

Pila Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Pila Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Pila Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Pila Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Pila Pharma stock

EBIT of Pila Pharma is -7.89 M SEK in 2025.

EBIT of Pila Pharma changed from -8.11 M SEK to -7.89 M SEK, representing a -2.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Pila Pharma since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Pila Pharma historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Pila Pharma

All Key Metrics — Pila Pharma